Direct medical costs associated with rheumatoid arthritis in Turkey: Analysis from National Claims Database

Rheumatology International

Volumn 33, Issue 10, 2013, Pages 2577-2584

  Baser, Onur ^a,b   Burkan, Abdulkadir ^c   Baser, Erdem ^d   Koselerli, Rasim ^c   Ertugay, Emre ^c   Altinbas, Akif ^e  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b STATINMED RESEARCH   (United States)

^c Social Security Institution   (Turkey)

^d CENTRAL BANK OF THE REPUBLIC OF TURKEY   (Turkey)

^e DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Medical costs; Outcomes research; Real word data analysis; Rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD SALT; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

ADULT; AGE DISTRIBUTION; AGED; ALLERGY; ARTICLE; BIOLOGICAL THERAPY; CARDIOVASCULAR DISEASE; COMORBIDITY; DATA BASE; DIABETES MELLITUS; DISEASE ACTIVITY SCORE; DISEASE SEVERITY; ELIXHAUSER COMORBIDITY INDEX; FEMALE; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; ICD-10-CM; INCIDENCE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE; NATIONAL HEALTH INSURANCE; OUTPATIENT; PHARMACY; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TURKEY (REPUBLIC);

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DATABASES, FACTUAL; FEMALE; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; TURKEY;

EID: 84885387920     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-013-2782-4     Document Type: Article

References (28)

1. Markenson JA (1991) Worldwide trends in the socioeconomic impact and long-term prognosis of rheumatoid arthritis. Semin Arthr Rheum 21(2 suppl 1):4-12
2. Lundkvist J, Kastäng F, Kobelt G (2008) The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 8:49-60
3. Jönsson B, Kobelt G, Smolen J (2008) The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. Eur J Health Econ 8(suppl 2):s61-s86
4. Singer RB (1998) Mortality in rheumatoid arthritis: experience in four clinical series compared with the experience in the 1983 medical impairment study. J Insur Med 30(2):88-95
5. Alarcón GS (1995) Epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 21(3):589-604
6. Yazici Y, Shi N, John A (2008) Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Bull NYU Hosp Jt Dis 66(2):77-85
7. Guillemin F, Durieux S, Daures JP et al (2004) Costs of rheumatoid arthritis in France: a multicenter study of 1,109 patients managed by hospital-based rheumatologists. J Rheumatol 31(7):1297-1304
8. Verstappen SM, Verkleij H, Bijlsma JW et al (2004) Determinants of direct costs in Dutch rheumatoid arthritis patients. Ann Rheum Dis 63(7):817-824
9. Westhovens R, Boonen A, Verbruggen L et al (2005) Healthcare consumption and direct costs of rheumatoid arthritis in Belgium. Clin Rheumatol 24(6):615-619
10. Cooper NJ (2000) Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 39(1):28-33
11. Akkoc N, Akar S (2006) Epidemiology of rheumatoid arthritis in Turkey. Clin Rheumatol 25(4):560-561
12. Malhan S, Akbulut LA, Bodur H, Tulunay CF (2010) Annual costs of rheumatoid arthritis in Turkey. Rheumatol Int 30(5):637-641
13. Malhan S, Pay S, Ataman S et al (2012) The cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care rheumatology units in Turkey. Clin Exp Rheumatol 30(2):202-207
14. Akdag R (2008) Progress Report 2008 Health Transformation Programme. Ministry of Health, Ankara
15. MacLean CH, Louie R, Leake B et al (2000) Quality of care for patients with rheumatoid arthritis. JAMA 284(8):984-992
16. Elixhauser A, Steiner C, Harris DR, Coffey RM (1998) Comorbidity measures for use with administrative data. Med Care 36:8-27
17. Baser O, Palmer L, Stephenson J (2008) The estimation power of alternative comorbidity indices. Value Health 11(5):946-955
18. Southern DA, Quan H, Ghali WA (2004) Comparison of the Elixhauser and Charlson/Deyo methods of comorbidity measurement in administrative data. Med Care 42(4):355-360
19. Manning WG, Mullahy J (2001) Estimating log models: to transform or not to transform? J Health Econ 20(4):461-494
20. Wooldridge JM (2006) Introductory econometrics: a modern approach, 3rd edn. Thomson/South-Western, Mason
21. Baser O (2009) Modeling transformed health care costs with unknown heteroskedasticity. Appl Econ Res Bull 01:1-6
22. Cakir N, Dervis E, Benian O et al (2004) Prevalence of Behçet's disease in rural western Turkey: a preliminary report. Clin Exp Rheumatol 22(4 suppl 34):s53-s55
23. Baser O, Baser E, Atinbas A, Burkan A (2013) Severity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in Turkey. Health Econ Rev 3:1-7
24. Benson K, Hartz AJ (2000) A comparison of observational studies and randomized, controlled trials. N Engl J Med 342(25):1878-1886
25. Gabriel SE (1994) The sensitivity and specificity of computerized databases for the diagnosis of rheumatoid arthritis. Arthr Rheum 37(6):821-823
26. Katz JN, Barrett J, Liang MH et al (1997) Sensitivity and positive predictive value of Medicare Part B physician claims for rheumatologic diagnoses and procedures. Arthr Rheum 40(9):1594-1600
27. Weiner J, Powe NR, Steinwachs DM, Dent G (1990) Applying insurance claims data to assess quality of care: a compilation of potential indicators. QRB Qual Rev Bull 16(12):424-438
28. Romano PS, Luft HS (1992) Getting the most out of messy data: problems and approaches for dealing with large administrative data sets. Medical Effectiveness Research Data Methods. AHCPR Pub. No. 92-0056. Rockville, Md, Public Health Service